GRFS

Stats

Summary

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t

Market Cap: 1.43 Billion

Primary Exchange: NASDAQ

Website: http://www.grifols.com/es/web/international/home

Shares Outstanding: 261 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.0623561934590648

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1265 trading days

From: 2020-02-21 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated
2019-12-02	2019-12-11	2019-12-03		0.220412	Cash
2020-10-30	2020-11-09	2020-11-02		0.201439	Cash
2020-10-30	2020-11-09	2020-11-02			Cash
2021-06-03	2021-06-14	2021-06-04		0.43849	Cash

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2016-01-04		2015-12-31	2016-01-08 00:00:00 -0500	0.5	2.0	1.0